Skip to main content

Amyotrophic Lateral Sclerosis (ALS) and cannabis in Kentucky

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
30-day supply as certif…
POSSESSION
$25/yr
STATE FEE
14–45 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Kentucky statute and program

The Kentucky Medical Cannabis Program is the operating authority for Kentucky patient certification. The authoritative legal text is: KRS Chapter 218B: Medical Cannabis (SB 47 of 2023).

What the evidence says about cannabis and Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that destroys motor neurons in the brain and spinal cord, leading to loss of voluntary muscle control. Symptoms typically include muscle weakness, spasticity, fasciculations, dysphagia, and respiratory compromise. Most patients survive 2–5 years from diagnosis.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Amyotrophic Lateral Sclerosis (ALS) page.

How to qualify in Kentucky

The Kentucky Medical Cannabis Program requires the following registration steps for a Amyotrophic Lateral Sclerosis (ALS) patient (or any qualifying diagnosis):

  1. See a Kentucky-licensed medical cannabis practitioner. Under SB 47 (2023), a Kentucky-licensed physician, advanced practice registered nurse, physician assistant, or optometrist who has completed the Kentucky Cabinet for Health and Family Services medical cannabis practitioner course and registered with the Office of Medical Cannabis may certify a patient. Qualifying conditions include any cancer, chronic, severe, intractable, or debilitating pain, epilepsy or other intractable seizure disorder, MS, muscle spasms or spasticity, chronic nausea or cyclical vomiting, and PTSD (KRS 218B.015).
  2. Apply through the Office of Medical Cannabis patient portal. The patient creates an account in the Kentucky Office of Medical Cannabis (OMC) registry portal. The certifying practitioner submits the written certification electronically; the patient then completes the patient registration with a Kentucky driver license or state ID and a passport-style photograph.
  3. Pay the state registration fee. The Kentucky medical cannabis patient registry card fee is $25 annually (caregiver registration is also $25 with a separate background check). Fees are paid online through the OMC portal. The program launched January 1, 2025; patients should expect rule updates during the program’s first operating year.
  4. Receive the card and purchase from a Kentucky dispensary. Kentucky medical cannabis registry cards are issued within roughly 30 days of complete application. Patients may purchase up to a 30-day supply from any licensed Kentucky medical cannabis dispensary. Kentucky does not authorize raw plant material for smoking; permitted forms include edibles, capsules, tinctures, vape products, topicals, and concentrates. Kentucky does not honor out-of-state medical cards.
State registration fee
$25
Physician visit (typical)
$200–$350
Certification to card
14–45 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Kentucky registration steps, fees, and reciprocity rules, see the Kentucky cannabis-laws page.

ICD-10 code

A certifying physician documenting Amyotrophic Lateral Sclerosis (ALS) for the Kentucky medical cannabis program will typically record ICD-10 G12.21 or SNOMED-CT 86044005 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Kentucky list Amyotrophic Lateral Sclerosis (ALS) as a qualifying condition for medical cannabis?

Yes. Kentucky explicitly lists Amyotrophic Lateral Sclerosis (ALS) as a qualifying condition under Kentucky Medical Cannabis Program. A patient with a documented Amyotrophic Lateral Sclerosis (ALS) diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Kentucky rules.

How do I get a Kentucky medical marijuana card for Amyotrophic Lateral Sclerosis (ALS)?

Step one is finding a physician licensed in Kentucky who is registered with Kentucky Medical Cannabis Program and willing to evaluate Amyotrophic Lateral Sclerosis (ALS) cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Kentucky does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Amyotrophic Lateral Sclerosis (ALS)?

For Amyotrophic Lateral Sclerosis (ALS), evidence is described as limited (a small number of supportive studies, often underpowered or focused on narrow symptom domains). The mmjnow condition page for Amyotrophic Lateral Sclerosis (ALS) lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Amyotrophic Lateral Sclerosis (ALS) should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Amyotrophic Lateral Sclerosis (ALS) and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Amyotrophic Lateral Sclerosis (ALS); the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. KRS Chapter 218B: Medical Cannabis (SB 47 of 2023)accessed May 16, 2026
  2. Kentucky Cabinet for Health and Family Services: Medical Cannabisaccessed May 16, 2026
  3. Wikipedia: Cannabis in Kentuckyaccessed May 16, 2026
  4. KRS Chapter 218A: Kentucky Controlled Substances Act (possession penalty schedule)accessed May 17, 2026
  5. Kentucky Department of Agriculture: Industrial Hemp Programaccessed May 17, 2026
  6. Kentucky General Assembly bill trackeraccessed May 17, 2026
  7. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026
  8. ALS Association: Cannabis and ALSaccessed May 15, 2026